HRT Financial’s Sarepta Therapeutics SRPT Stock Holding History

HRT Financial’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,700	Closed	-$273K	–	4676
2025 Q4	$273K	Buy	+12,700	New	+$268K	﹤0.01%	2432

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial's SRPT Position: Q1 2026 in Review

HRT Financial sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 294,112 shares — an estimated $5.69M sold.

HRT Financial first reported a position in SRPT in Q4 2020 and held it in 11 quarters. The position peaked at $10.6M in Q1 2023. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

HRT Financial reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 294,112 Sarepta Therapeutics shares in Q1 2026, an estimated $5.69M.
HRT Financial first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 11 quarters.
HRT Financial's Sarepta Therapeutics position peaked at $10.6M in Q1 2023.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.